Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (181-190 of 222) with videos related to

Pageof 23
Sort By:
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
The Journal of Investigative Dermatology|August 7, 2022
Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non‒Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular PsoriasisClaire Q Wang, Sokol Haxhinasto, Sandra Garcet, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus DocumentMelinda J Gooderham, Chih-Ho Hong, Lorne Albrecht, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic DermatitisChih-Ho Hong, Melinda J Gooderham, Lorne Albrecht, et al.
The Journal of Allergy and Clinical Immunology|July 30, 2019
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitisAna B Pavel, Teresa Song, Hyun-Je Kim, et al.
Journal of Cutaneous Medicine and Surgery|March 20, 2024
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National SurveyErika Y Lee, Irina Turchin, An-Wen Chan, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
American Journal of Clinical Dermatology|June 20, 2020
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 23, 2023
Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis SkinDonald Y M Leung, Robert Bissonnette, Simion Kreimer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.
Pageof 23

Showing results (181-190 of 222) with videos related to

Sort By:
Pageof 23
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
The Journal of Investigative Dermatology|August 7, 2022
Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non‒Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular PsoriasisClaire Q Wang, Sokol Haxhinasto, Sandra Garcet, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus DocumentMelinda J Gooderham, Chih-Ho Hong, Lorne Albrecht, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic DermatitisChih-Ho Hong, Melinda J Gooderham, Lorne Albrecht, et al.
The Journal of Allergy and Clinical Immunology|July 30, 2019
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitisAna B Pavel, Teresa Song, Hyun-Je Kim, et al.
Journal of Cutaneous Medicine and Surgery|March 20, 2024
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National SurveyErika Y Lee, Irina Turchin, An-Wen Chan, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
American Journal of Clinical Dermatology|June 20, 2020
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 23, 2023
Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis SkinDonald Y M Leung, Robert Bissonnette, Simion Kreimer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.
Pageof 23